APA (7th ed.) Citation

Wu, S., Chang, T., Tsai, M., Liu, Y., Huang, Y., Hsu, C., . . . Shih, J. (2024). miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44. Molecular therapy. Nucleic acids, 35(1), 102091. https://doi.org/10.1016/j.omtn.2023.102091

Chicago Style (17th ed.) Citation

Wu, Shang-Gin, Tzu-Hua Chang, Meng-Feng Tsai, Yi-Nan Liu, Yen-Lin Huang, Chia-Lang Hsu, Han-Nian Jheng, and Jin-Yuan Shih. "MiR-204 Suppresses Cancer Stemness and Enhances Osimertinib Sensitivity in Non-small Cell Lung Cancer by Targeting CD44." Molecular Therapy. Nucleic Acids 35, no. 1 (2024): 102091. https://doi.org/10.1016/j.omtn.2023.102091.

MLA (9th ed.) Citation

Wu, Shang-Gin, et al. "MiR-204 Suppresses Cancer Stemness and Enhances Osimertinib Sensitivity in Non-small Cell Lung Cancer by Targeting CD44." Molecular Therapy. Nucleic Acids, vol. 35, no. 1, 2024, p. 102091, https://doi.org/10.1016/j.omtn.2023.102091.